Eli Lilly announced multiple new partnerships, including expanding Zepbound access with CVS Health, collaborating with Insilico Medicine, and investing in an AI lab with NVIDIA.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly announced multiple new partnerships, including expanding Zepbound access with CVS Health, collaborating with Insilico Medicine, and investing in an AI lab with NVIDIA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
CVS Health
company
-
Insilico Medicine
American biotechnology company
Nothing else this week.
Related events
- CVS Health is expanding its drug offerings to include Eli Lilly's Zepbound and Novo Nordisk's Wegovy, while also considering an investment in Roche.
- Eli Lilly and Company is collaborating with Nvidia and OpenAI to build an AI lab aimed at accelerating drug discovery.
- Veeva Systems, Eli Lilly and Company, and Salesforce renewed a global partnership focused on AI adoption and migrating from legacy infrastructure.
- Soutrik Banerjee is currently employed as a consultant at Eli Lilly and Company.
- Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.